revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
Company profile
Ticker
RVNC
Exchange
Website
CEO
Mark Foley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1.Hint, Inc. ...
RVNC stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
9 May 24
8-K
Submission of Matters to a Vote of Security Holders
3 May 24
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
8-K
Other Events
5 Mar 24
424B5
Prospectus supplement for primary offering
5 Mar 24
424B5
Prospectus supplement for primary offering
4 Mar 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
Transcripts
RVNC
Earnings call transcript
2024 Q1
9 May 24
RVNC
Earnings call transcript
2023 Q4
28 Feb 24
RVNC
Earnings call transcript
2023 Q3
8 Nov 23
RVNC
Earnings call transcript
2023 Q2
8 Aug 23
RVNC
Earnings call transcript
2023 Q2
8 Aug 23
RVNC
Earnings call transcript
2023 Q1
9 May 23
RVNC
Earnings call transcript
2022 Q4
28 Feb 23
RVNC
Earnings call transcript
2022 Q3
9 Nov 22
RVNC
Earnings call transcript
2022 Q2
10 Aug 22
RVNC
Earnings call transcript
2022 Q1
11 May 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 139.93 mm | 139.93 mm | 139.93 mm | 139.93 mm | 139.93 mm | 139.93 mm |
Cash burn (monthly) | 1.61 mm | 347.42 k | 15.61 mm | 25.46 mm | 21.98 mm | 17.75 mm |
Cash used (since last report) | 3.10 mm | 670.28 k | 30.11 mm | 49.13 mm | 42.41 mm | 34.25 mm |
Cash remaining | 136.83 mm | 139.26 mm | 109.81 mm | 90.80 mm | 97.52 mm | 105.68 mm |
Runway (months of cash) | 85.2 | 400.8 | 7.0 | 3.6 | 4.4 | 6.0 |
Institutional ownership, Q1 2024
12.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 62 |
Opened positions | 19 |
Closed positions | 98 |
Increased positions | 15 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 18.52 bn |
Total shares | 13.48 mm |
Total puts | 249.40 k |
Total calls | 190.70 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Teoxane | 6.55 mm | $60.73 mm |
JPM JPMorgan Chase & Co. | 2.77 mm | $0.00 |
Rice Hall James & Associates | 746.14 k | $3.67 bn |
Essex Woodlands Health Ventures VIII, L.L.C. | 457.09 k | $13.11 mm |
HighTower Advisors | 445.39 k | $2.19 bn |
BK Bank Of New York Mellon | 304.56 k | $1.50 bn |
AlphaCentric Advisors | 245.00 k | $1.21 bn |
Essex Investment Management | 220.16 k | $1.08 bn |
BNP Paribas Arbitrage | 211.70 k | $1.04 bn |
Assenagon Asset Management | 198.85 k | $978.32 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 24 | Beraud Jill | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 43,606 |
1 May 24 | Beraud Jill | Stock Option Common Stock | Grant | Acquire A | No | No | 3.795 | 23,458 | 89.02 k | 23,458 |
1 May 24 | Coric Vlad | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 20,784 |
1 May 24 | Coric Vlad | Stock Option Common Stock | Grant | Acquire A | No | No | 3.795 | 23,458 | 89.02 k | 23,458 |
1 May 24 | Gangolli Julian S | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 45,106 |
1 May 24 | Gangolli Julian S | Stock Option Common Stock | Grant | Acquire A | No | No | 3.795 | 23,458 | 89.02 k | 23,458 |
1 May 24 | Chris Nolet | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 43,606 |
1 May 24 | Chris Nolet | Stock Option Common Stock | Grant | Acquire A | No | No | 3.795 | 23,458 | 89.02 k | 23,458 |
1 May 24 | Carey OConnor Kolaja | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 31,561 |
1 May 24 | Carey OConnor Kolaja | Stock Option Common Stock | Grant | Acquire A | No | No | 3.795 | 23,458 | 89.02 k | 23,458 |
News
HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Lowers Price Target to $11
13 May 24
Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
13 May 24
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
10 May 24
12 Health Care Stocks Moving In Friday's Intraday Session
10 May 24
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
10 May 24
Press releases
Revance to Participate in Upcoming Investor Conferences
28 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
9 May 24
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
9 May 24
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
2 May 24
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
12 Apr 24